Clinical Trials Logo

Lupus Erythematosus, Systemic clinical trials

View clinical trials related to Lupus Erythematosus, Systemic.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT04907175 No longer available - Clinical trials for System; Lupus Erythematosus

Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)

Start date: n/a
Phase:
Study type: Expanded Access

This protocol is part of an FDA Individual Patient Expanded Access IND. This study is to be conducted according to US and International Standards of Good Clinical Practice (FDA Title 21 part 312 and International Conference on Harmonization guidelines), applicable government regulations and Hope Biosciences Stem Cell Research Foundation policies and procedures.

NCT ID: NCT04750057 No longer available - Clinical trials for Systemic Lupus Erythematosus

Anifrolumab Early Access Program

AMANA
Start date: n/a
Phase:
Study type: Expanded Access

To provide early access (ie, before marketing authorisation) to anifrolumab 300 mg IV Q4W while receiving standard therapy in adult patients with moderate-to-severe active SLE

NCT ID: NCT03125486 No longer available - Clinical trials for Systemic Lupus Erythematosus

Compassionate Use for Subcutaneous (SC) Belimumab

Start date: n/a
Phase: N/A
Study type: Expanded Access

GlaxoSmithKline (GSK) have submitted a Biologic License Application (BLA) for the subcutaneous formulation of belimumab which is currently under review by the Food and Drug Administration (FDA). The goal of this individual patient compassionate use supply is to provide a patient with subcutaneous belimumab for the period of 1 year or until the subcutaneous formulation of belimumab becomes approved for use by the FDA and is commercially available to this patient, whichever is sooner. You can access GSK's Policy on Compassionate via http://www.gsk.com/media/3368/compassionate-use.pdf.